Send me a link:

*Text messaging rates may apply.

 Dow Up0.36% Nasdaq Up0.71%

Vertex Pharmaceuticals Incorporated (VRTX)

-NasdaqGS
97.74 1.43(1.48%) Jul 22, 3:59PM EDT
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingDec 31, 2013Dec 31, 2012Dec 31, 2011
Total Revenue 1,211,975   1,527,042   1,410,626  
Cost of Revenue130,277  279,885  80,505  
Gross Profit 1,081,698   1,247,157   1,330,121  
Operating Expenses
Research Development918,783  806,185  707,706  
Selling General and Administrative362,342  436,796  400,721  
Non Recurring704,021  1,844  107,874  
Others -   -   -  
Total Operating Expenses -   -   -  
Operating Income or Loss (903,448) 2,332   113,820  
Income from Continuing Operations
Total Other Income/Expenses Net(49,939)309  (15,694)
Earnings Before Interest And Taxes(953,387)2,641  98,126  
Interest Expense22,730  15,022  37,681  
Income Before Tax(976,117)(12,381)60,445  
Income Tax Expense(288,567)38,754  19,266  
Minority Interest242,522  (55,897)(11,605)
Net Income From Continuing Ops(445,028)(107,032)29,574  
Non-recurring Events
Discontinued Operations -   -   -  
Extraordinary Items -   -   -  
Effect Of Accounting Changes -   -   -  
Other Items -   -   -  
Net Income (445,028) (107,032) 29,574  
Preferred Stock And Other Adjustments -   -   -  
Net Income Applicable To Common Shares (445,028) (107,032) 29,574  

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.